Itraconazole analogs and use thereof
US-11028078-B2 · Jun 8, 2021 · US
Itraconazole analogs and use thereof
US12545666B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12545666-B2 |
| Application number | US-202117245875-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 30, 2021 |
| Priority date | Sep 7, 2011 |
| Publication date | Feb 10, 2026 |
| Grant date | Feb 10, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from: Compound Structure Number 208 214 215 or an optically pure stereoisomer or pharmaceutically acceptable salt thereof, wherein the cancer is selected from prostate cancer, non-small cell lung cancer, and basal cell carcinoma. 2 . The method of claim 1 , wherein when the cancer is prostate cancer or non-small cell lung cancer, the compound is administered via oral or parenteral administration; and wherein when the cancer is basal cell carcinoma, the compound is administered via oral, parenteral, or topical administration.
Assignees
Inventors
Classifications
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
not condensed and containing further heterocyclic rings · CPC title
- C07D405/14Primary
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12545666B2 cover?
- Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification C07D405/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).